Though non-small cell lung cancers (NSCLCs), approximately 85% of all lung cancers, have been treated for recent decades by multimodality treatments consisting of extended surgical resection, radiotherapy and chemotherapy, a five-year survival rate is still considered below 20% in NSCLC with multiple mutations, including KRAS and epidermal growth factor receptor (EGFR) [1,2]. This evidence concerns the gene EGFR and lung cancer.